Golden Reserve Retirement LLC Invests $1.68 Million in AbbVie Inc. $ABBV

Key Points

• Golden Reserve Retirement LLC opened a new position in AbbVie, buying 7,346 shares in Q4 valued at about $1.68 million, representing 0.3% of the firm's holdings and AbbVie's 13th largest holding for the fund.
• AbbVie beat Q4 estimates with $2.71 EPS on $16.62 billion revenue and has set FY 2026 guidance of 14.370–14.570 EPS (Q1 guidance 2.97–3.01), while analysts forecast roughly 14.21 EPS for the year.
• The U.S. FDA issued a Complete Response Letter (CRL) for AbbVie's trenibotulinumtoxinE citing manufacturing/process issues, delaying potential commercialization and creating near-term regulatory uncertainty.

Golden Reserve Retirement LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,346 shares of the company's stock, valued at approximately $1,678,000. AbbVie makes up 0.3% of Golden Reserve Retirement LLC's holdings, making the stock its 13th largest holding.

A number of other institutional investors and hedge funds have also bought and sold shares of ABBV. Brighton Jones LLC increased its holdings in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its holdings in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. increased its holdings in AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock valued at $3,056,000 after purchasing an additional 789 shares during the period. Ieq Capital LLC increased its holdings in AbbVie by 4.6% in the second quarter. Ieq Capital LLC now owns 120,035 shares of the company's stock valued at $22,281,000 after purchasing an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC increased its holdings in AbbVie by 117.3% in the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company's stock valued at $210,685,000 after purchasing an additional 612,702 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 1.1%

Shares of AbbVie stock opened at $198.71 on Friday. The business has a 50-day moving average price of $216.68 and a two-hundred day moving average price of $222.40. AbbVie Inc. has a 1-year low of $176.57 and a 1-year high of $244.81. The company has a market cap of $351.35 billion, a P/E ratio of 84.20, a PEG ratio of 0.72 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period last year, the business posted $2.16 EPS. The business's revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 14.21 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is presently 293.22%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a major strategic investment: a $1.4 billion, AI-enabled manufacturing campus in Durham, NC that will create hundreds of permanent jobs and supports capacity for immunology, neuroscience and oncology medicines. This strengthens manufacturing footprint and long-term growth/production capacity. Article Title
• Positive Sentiment: Canaccord initiated coverage with a Buy and $262 price target (recent coverage highlighted AbbVie as a buy on pullback), providing bullish analyst support and upside from current levels. Analyst upgrades can buoy sentiment and attract inflows. Article Title
• Positive Sentiment: AbbVie struck an exclusive licensing deal with Haisco for development of pain medicines, expanding its pipeline and potential addressable market for pain therapeutics. Partnership deals can add optionality to future revenue. Article Title
• Neutral Sentiment: Wall Street previews and model-level estimates for Q1 (sales and key metric breakdowns) are circulating ahead of AbbVie’s April 29 earnings; these projections set expectations traders will use for the report. Meeting or beating estimates could stabilize the stock. Article Title
• Neutral Sentiment: Analysts and media continue to discuss AbbVie as a dividend-growth candidate and a long-term defensive healthcare holding; this maintains baseline investor interest but is unlikely to move shares sharply near-term. Article Title
• Negative Sentiment: The U.S. FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) — citing manufacturing/process issues rather than new clinical trials. AbbVie said it will respond and believes it can address comments, but the CRL delays potential commercialization and near-term revenue expectations for the neurotoxin program. Article Title
• Negative Sentiment: Multiple outlets report the CRL is tied to manufacturing concerns; while AbbVie noted no additional clinical studies were requested, regulatory manufacturing issues create uncertainty on timing and cost to obtain approval — a near-term headwind for sentiment. Article Title

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price objective for the company. Piper Sandler decreased their price objective on AbbVie from $299.00 to $294.00 and set an "overweight" rating for the company in a report on Thursday. BMO Capital Markets restated an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Evercore decreased their price objective on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a report on Wednesday, February 4th. Finally, Citigroup decreased their price objective on AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a report on Tuesday, January 27th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $253.19.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.